Amgen has revealed ground-breaking findings from its Phase 3 DeLLphi-304 clinical trial, showing that Imdelltra® (tarlatamab-dlle) dramatically decreased the risk of death in patients with extensive-stage small cell lung cancer (ES-SCLC) by 40% when compared to standard chemotherapy. Patients whose illness had worsened after receiving platinum-based chemotherapy were included in the trial.
The trial’s primary aim was successfully met by Imdelltra, a first-in-class DLL3-targeting BiTE® molecule, which demonstrated a statistically significant and clinically relevant overall survival (OS) advantage over conventional chemotherapy.
The median overall survival (OS) for patients in the Imdelltra group was 14.3 months, while that of patients in the chemotherapy arm was 9.6 months. Progress-free survival (PFS), the secondary goal, was also achieved, with the Imdelltra arm showing a notable improvement. Cytokine release syndrome (CRS) was the most often reported treatment-related adverse event, and the safety profile was in line with previous research. Early in the course of treatment, the majority of CRS patients were low grade.
Small cell lung cancer is an extraordinarily aggressive and difficult-to-treat disease, and those living with SCLC often experience limited benefit with first line treatment,
These data underscore IMDELLTRA’s potential to transform patient outcomes and the small cell lung cancer treatment paradigm.
Jay Bradner
The data from DeLLphi-304 mark a major milestone for people with relapsed small cell lung cancer. Tarlatamab is associated with significant improvements in both overall and progression-free survival over standard chemotherapy in patients with recurrent or progressive disease,
This study also provides confirmatory data on management of potential toxicities associated with bispecific T-cell engager therapies in a large patient cohort, which is crucial to continuing to improve the experience of patients treated with these medicines.
Charles Rudin
In a crucial trial for SCLC, Imdelltra—the first and only DLL3-targeting bispecific T-cell engager treatment with regulatory approval—showed an overall survival benefit. In May 2024, Imdelltra received accelerated approval from the U.S. Food and Drug Administration to treat adult patients with ES-SCLC whose disease has advanced during or following platinum-based chemotherapy. The goal of the DeLLphi-304 study is to facilitate a complete approval.
Last Modified:
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
